ALK-5 inhibitors and uses thereof

US11746103B2 · kind B2 · utility

Assignee

• Sumitomo Pharma Oncology, Inc. · US

Inventors

• Bettina Franz · Orem, US
• Adam Siddiqui-Jain · South Jordan, US
• Steven L. Warner · Sandy, US
• Siva Reddy Basireddy · Chilpur, IN
• Srinivas Padakanti · Darsi, IN
• Naresh Kumar · Barwala, IN

Key dates

• Filing date: Apr 29, 2022
• Grant date: Sep 5, 2023
• Expiry date: Apr 29, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are compounds (e.g., compounds of Formulae (I), (II), (III) and (IV), or of Table 1 or Table 4), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and kits comprising the same. The compounds provided herein are activin receptor-like kinase (e.g., ALK-5) inhibitors and are, therefore, useful, for example, for treating and/or preventing diseases (e.g., proliferative diseases, such as cancer) in a subject, inhibiting tumor growth in a subject, or inhibiting the activity of an activin receptor-like kinase (e.g., ALK-5) in vitro or in vivo. Also provided herein are methods and synthetic intermediates useful in the preparation of compounds described herein.